Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Sex work among female workers in the traditional mining sector in Mali - results from the ANRS-12339 Sanu Gundo cross-sectional study in 2015.

Kounta CH, Sagaon-Teyssier L, Balique H, Diallo F, Kalampalikis N, Mora M, Bourrelly M, Suzan-Monti M, Spire B, Keita BD.

Afr J AIDS Res. 2019 Sep;18(3):215-223. doi: 10.2989/16085906.2019.1653330.

PMID:
31575341
2.

Becoming adherent to a preventive treatment for HIV: a qualitative approach.

Puppo C, Mabire X, Morel S, Laguette V, Rojas Castro D, Chas J, Cua E, Pintado C, Suzan-Monti M, Spire B, Molina JM, Préau M.

Psychol Health Med. 2019 Jul 11:1-12. doi: 10.1080/13548506.2019.1640886. [Epub ahead of print]

PMID:
31294630
3.

Intimate partner violence against HIV-positive Cameroonian women: Prevalence, associated factors and relationship with antiretroviral therapy discontinuity-results from the ANRS-12288 EVOLCam survey.

Fiorentino M, Sagaon-Teyssier L, Ndiaye K, Suzan-Monti M, Mengue MT, Vidal L, Kuaban C, March L, Laurent C, Spire B, Boyer S; EVOLCam Study Group.

Womens Health (Lond). 2019 Jan-Dec;15:1745506519848546. doi: 10.1177/1745506519848546.

4.

A generalized additive model to disentangle age and diagnosis-specific cohort effects in psychological and behavioral outcomes in people living with HIV: the French cross-sectional ANRS-VESPA2 survey.

Sagaon-Teyssier L, Vilotitch A, Mora M, Maradan G, Guagliardo V, Suzan-Monti M, Dray-Spira R, Spire B; VESPA2 study group.

BMC Public Health. 2019 May 17;19(1):590. doi: 10.1186/s12889-019-6905-z.

5.

Pleasure and PrEP: Pleasure-Seeking Plays a Role in Prevention Choices and Could Lead to PrEP Initiation.

Mabire X, Puppo C, Morel S, Mora M, Rojas Castro D, Chas J, Cua E, Pintado C, Suzan-Monti M, Spire B, Molina JM, Préau M.

Am J Mens Health. 2019 Jan-Feb;13(1):1557988319827396. doi: 10.1177/1557988319827396.

6.

Is on-Demand HIV Pre-exposure Prophylaxis a Suitable Tool for Men Who Have Sex With Men Who Practice Chemsex? Results From a Substudy of the ANRS-IPERGAY Trial.

Roux P, Fressard L, Suzan-Monti M, Chas J, Sagaon-Teyssier L, Capitant C, Meyer L, Tremblay C, Rojas-Castro D, Pialoux G, Molina JM, Spire B.

J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):e69-e75. doi: 10.1097/QAI.0000000000001781.

PMID:
30212434
7.

Changes in supervised drug-injecting practices following a community-based educational intervention: A longitudinal analysis.

Mezaache S, Protopopescu C, Debrus M, Morel S, Mora M, Suzan-Monti M, Rojas Castro D, Carrieri P, Roux P.

Drug Alcohol Depend. 2018 Nov 1;192:1-7. doi: 10.1016/j.drugalcdep.2018.07.028. Epub 2018 Sep 5.

PMID:
30195241
8.

The ANRS-Ipergay trial, an opportunity to use qualitative research to understand the perception of the "participant"-physician relationship.

Di Ciaccio M, Protiere C, Rojas Castro D, Suzan-Monti M, Chas J, Cotte L, Siguier M, Cua E, Spire B, Molina JM, Preau M; ANRS IPERGAY Study Group.

AIDS Care. 2018 Jun;30(sup2):41-47. doi: 10.1080/09540121.2018.1468013. Epub 2018 May 30.

PMID:
29848004
9.

Posttraumatic Stress Disorder as a Significant Correlate of Voluntary Antiretroviral Treatment Interruption in Adult HIV-Infected Patients Followed up in French Hospitals: Data From the ANRS-VESPA2 National Survey.

Roux P, Marcellin F, Ndiaye K, Suzan-Monti M, Mayet A, Duracinsky M, Briand-Madrid L, Maradan G, Mora M, Préau M, Verger P, Carrieri P, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

J Clin Psychiatry. 2018 May/Jun;79(3). pii: 17m11659. doi: 10.4088/JCP.17m11659.

PMID:
29659208
10.

Assessement of Awareness of, Concerns and Attitudes Towards HIV-Related Court-Case Sentences in France in a Representative Sample of People Living with HIV (ANRS VESPA2 Survey).

Suzan-Monti M, Celse M, Vilotitch A, Demoulin B, Dray-Spira R, Yéni P, Lert F, Spire B; ANRS VESPA2 study group.

AIDS Behav. 2018 Oct;22(10):3264-3272. doi: 10.1007/s10461-018-2077-6.

PMID:
29512033
11.

Factors associated with partner notification of STIs in men who have sex with men on PrEP in France: a cross-sectional substudy of the ANRS-IPERGAY trial.

Suzan-Monti M, Cotte L, Fressard L, Cua E, Capitant C, Meyer L, Pialoux G, Molina JM, Spire B; ANRS IPERGAY Study Group.

Sex Transm Infect. 2018 Nov;94(7):490-493. doi: 10.1136/sextrans-2017-053304. Epub 2018 Jan 29.

PMID:
29378903
12.

Renunciation of health care by people living with HIV in France is still associated with discrimination in health-care services and social insecurity - results from the ANRS-VESPA2 survey.

Fiorentino M, Suzan-Monti M, Vilotitch A, Sagaon-Teyssier L, Dray-Spira R, Lert F, Spire B; ANRS-VESPA2 Study Group.

Antivir Ther. 2018;23(5):443-450. doi: 10.3851/IMP3220.

PMID:
29360097
13.

Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC).

Preau M, Doumergue M, Protiere C, Goujard C, Mora M, Meyer L, Lelievre JD, Raffi F, Spire B, Lambotte O, Suzan-Monti M.

AIDS Care. 2018 Jul;30(7):914-920. doi: 10.1080/09540121.2018.1426825. Epub 2018 Jan 18.

PMID:
29347826
14.

Treatment interruption in HIV-positive patients followed up in Cameroon's antiretroviral treatment programme: individual and health care supply-related factors (ANRS-12288 EVOLCam survey).

Tong C, Suzan-Monti M, Sagaon-Teyssier L, Mimi M, Laurent C, Maradan G, Mengue MT, Spire B, Kuaban C, Vidal L, Boyer S; EVOL Cam group.

Trop Med Int Health. 2018 Mar;23(3):315-326. doi: 10.1111/tmi.13030. Epub 2018 Feb 2.

15.

Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC).

Protière C, Spire B, Mora M, Poizot-Martin I, Préau M, Doumergue M, Morlat P, Zucman D, Goujard C, Raffi F, Lambotte O, Suzan-Monti M.

PLoS One. 2017 Nov 2;12(11):e0187489. doi: 10.1371/journal.pone.0187489. eCollection 2017.

16.

Prevalence of HIV at the Kokoyo informal gold mining site: what lies behind the glitter of gold with regard to HIV epidemics in Mali? A community-based approach (the ANRS-12339 Sanu Gundo cross-sectional survey).

Sagaon-Teyssier L, Balique H, Diallo F, Kalampalikis N, Mora M, Bourrelly M, Suzan-Monti M, Spire B, Dembélé Keita B.

BMJ Open. 2017 Aug 3;7(8):e016558. doi: 10.1136/bmjopen-2017-016558.

17.

Importance of the patient-physician interaction in assessing acceptability of HIV cure trials.

Protière C, Préau M, Carrieri P, Lambotte O, Spire B, Suzan-Monti M.

HIV Med. 2018 Apr;19(4):e56-e57. doi: 10.1111/hiv.12526. Epub 2017 Jun 20. No abstract available.

PMID:
28631883
18.

Will CURE trials introduce an uncomfortable revolution in the field of HIV research?

Protière C, Préau M, Doumergue M, Mora M, Lambotte O, Spire B, Suzan-Monti M.

HIV Clin Trials. 2017 Jul;18(4):174-175. doi: 10.1080/15284336.2017.1331603. Epub 2017 Jun 6. No abstract available.

PMID:
28587569
19.

Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey).

Carrieri MP, Marcellin F, Fressard L, Préau M, Sagaon-Teyssier L, Suzan-Monti M, Guagliardo V, Mora M, Roux P, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

PLoS One. 2017 Feb 13;12(2):e0171645. doi: 10.1371/journal.pone.0171645. eCollection 2017.

20.

Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.

Valade E, Bouazza N, Lui G, Illamola SM, Benaboud S, Treluyer JM, Cobat A, Foissac F, De Sousa Mendes M, Chenevier-Gobeaux C, Suzan-Monti M, Rouzioux C, Assoumou L, Viard JP, Urien S, Ghosn J, Hirt D.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02062-16. doi: 10.1128/AAC.02062-16. Print 2017 Mar.

21.

Disclosure of HIV Status Beyond Sexual Partners by People Living with HIV in France: A Call for Help? Results from the National Cross-Sectional Survey ANRS-VESPA2.

Marcellin F, Suzan-Monti M, Vilotitch A, Sagaon-Teyssier L, Mora M, Dray-Spira R, Préau M, Lert F, Spire B; ANRS VESPA2 Study Group.

AIDS Behav. 2017 Jan;21(1):196-206. doi: 10.1007/s10461-016-1549-9.

PMID:
27614877
22.

Informal pre-exposure prophylaxis use in France: results from the Flash PrEP survey (2014).

Rojas Castro D, Quatremere G, Sagaon-Teyssier L, Le Gall JM, Preau M, Suzan-Monti M, Spire B.

HIV Med. 2017 Apr;18(4):308-310. doi: 10.1111/hiv.12419. Epub 2016 Aug 1. No abstract available.

23.

Larger is not necessarily better! Impact of HIV care unit characteristics on virological success: results from the French national representative ANRS-VESPA2 study.

Sagaon-Teyssier L, Fressard L, Mora M, Maradan G, Guagliardo V, Suzan-Monti M, Dray-Spira R, Spire B; VESPA2 Study Group.

Health Policy. 2016 Aug;120(8):936-47. doi: 10.1016/j.healthpol.2016.07.003. Epub 2016 Jul 14.

PMID:
27450774
24.

HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens.

Gantner P, Assoumou L, Leruez-Ville M, David L, Suzan-Monti M, Costagliola D, Rouzioux C, Ghosn J; EVARIST ANRS EP 49 Study Group.

J Antimicrob Chemother. 2016 Nov;71(11):3202-3205. Epub 2016 Jul 17.

PMID:
27432601
25.

Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study.

Roux P, Rojas Castro D, Ndiaye K, Debrus M, Protopopescu C, Le Gall JM, Haas A, Mora M, Spire B, Suzan-Monti M, Carrieri P.

PLoS One. 2016 Jun 13;11(6):e0157062. doi: 10.1371/journal.pone.0157062. eCollection 2016.

26.

Sexual Behavior with Serodiscordant Partners Among HIV-Positive Men Who Have Sex with Men Followed Up in Hospitals Between 2003 and 2011 in France: Results from a Repeated National Representative Survey (ANRS VESPA and VESPA2).

Suzan-Monti M, Sagaon-Teyssier L, Demoulin B, Vilotitch A, Préau M, Dray-Spira R, Lert F, Spire B.

AIDS Patient Care STDS. 2016 May;30(5):193-6. doi: 10.1089/apc.2016.0015. No abstract available.

PMID:
27158845
27.

Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.

Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente N, Préau M, Mora M, Rojas Castro D, Chidiac C, Chas J, Meyer L, Molina JM, Spire B; ANRS IPERGAY Study Group.

AIDS Care. 2016;28 Suppl 1:48-55. doi: 10.1080/09540121.2016.1146653. Epub 2016 Feb 17.

28.

Sexual risk behaviour among people living with HIV according to the biomedical risk of transmission: results from the ANRS-VESPA2 survey.

Suzan-Monti M, Lorente N, Demoulin B, Marcellin F, Préau M, Dray-Spira R, Lert F, Spire B; ANRS-VESPA2 Study Group.

J Int AIDS Soc. 2016 Jan 8;19(1):20095. doi: 10.7448/IAS.19.1.20095. eCollection 2016.

29.

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group.

N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.

30.

Risk Factors for HCV Reinfection or Transmission in HIV-HCV Coinfected MSM (ANRS-VESPA2 French National Survey).

Marcellin F, Demoulin B, Suzan-Monti M, Maradan G, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):e179-82. doi: 10.1097/QAI.0000000000000836. No abstract available.

PMID:
26569181
31.

Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.

Valade E, Tréluyer JM, Illamola SM, Bouazza N, Foissac F, De Sousa Mendes M, Lui G, Chenevier-Gobeaux C, Suzan-Monti M, Rouzioux C, Assoumou L, Viard JP, Hirt D, Urien S, Ghosn J; Evarist ANRS-EP 49 Study Group.

Antimicrob Agents Chemother. 2015 Nov;59(11):6800-6. doi: 10.1128/AAC.01517-15. Epub 2015 Aug 17.

32.

Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study.

Roux P, Le Gall JM, Debrus M, Protopopescu C, Ndiaye K, Demoulin B, Lions C, Haas A, Mora M, Spire B, Suzan-Monti M, Carrieri MP.

Addiction. 2016 Jan;111(1):94-106. doi: 10.1111/add.13089. Epub 2015 Sep 28.

PMID:
26234629
33.

Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).

Marcellin F, Demoulin B, Spire B, Suzan-Monti M, Roux P, Protopopescu C, Sagaon-Teyssier L, Duracinsky M, Dray-Spira R, Carrieri MP; ANRS-VESPA2 Study Group.

Expert Rev Gastroenterol Hepatol. 2015 May;9(5):701-13. doi: 10.1586/17474124.2015.1016914. Epub 2015 Feb 27.

PMID:
25723557
34.

Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau (ESTHER) substudy].

Suzan-Monti M, Blanche J, Boyer S, Kouanfack C, Delaporte E, Bonono RC, Carrieri PM, Protopopescu C, Laurent C, Spire B; Stratall ANRS 12110/ESTHER Study Group.

HIV Med. 2015 May;16(5):307-18. doi: 10.1111/hiv.12213. Epub 2015 Feb 27.

35.

Comparison of risk factors in HIV-infected men who have sex with men, coinfected or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey).

Marcellin F, Lorente N, Demoulin B, Carrieri MP, Suzan-Monti M, Roux P, Lert F, Sagaon-Teyssier L, Dray-Spira R, Spire B; ANRS VESPA2 Study Group.

Sex Transm Infect. 2015 Feb;91(1):21-3. doi: 10.1136/sextrans-2014-051542. Epub 2014 Aug 5.

PMID:
25096920
36.

Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys).

Douab T, Marcellin F, Vilotitch A, Protopopescu C, Préau M, Suzan-Monti M, Sagaon-Teyssier L, Lert F, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

AIDS Care. 2014;26 Suppl 1:S29-40. doi: 10.1080/09540121.2014.906553. Epub 2014 Apr 14.

PMID:
24731158
37.

HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens.

Ghosn J, Leruez-Ville M, Blanche J, Delobelle A, Beaudoux C, Mascard L, Lecuyer H, Canestri A, Landman R, Zucman D, Ponscarme D, Rami A, Viard JP, Spire B, Rouzioux C, Costagliola D, Suzan-Monti M; Evarist–ANRS EP 49 Study Group.

Clin Infect Dis. 2014 Jun;58(12):1763-70. doi: 10.1093/cid/ciu187. Epub 2014 Mar 18.

PMID:
24647014
38.

Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Meresse M, March L, Kouanfack C, Bonono RC, Boyer S, Laborde-Balen G, Aghokeng A, Suzan-Monti M, Delaporte E, Spire B, Carrieri MP, Laurent C; Stratall ANRS 12110/ESTHER Study Group.

HIV Med. 2014 Sep;15(8):478-87. doi: 10.1111/hiv.12140. Epub 2014 Mar 3.

39.

Expanding access to non-medicalized community-based rapid testing to men who have sex with men: an urgent HIV prevention intervention (the ANRS-DRAG study).

Lorente N, Preau M, Vernay-Vaisse C, Mora M, Blanche J, Otis J, Passeron A, Le Gall JM, Dhotte P, Carrieri MP, Suzan-Monti M, Spire B; ANRS-DRAG Study Group.

PLoS One. 2013 Apr 16;8(4):e61225. doi: 10.1371/journal.pone.0061225. Print 2013. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/73d8610b-c201-4889-889e-db0fba5a3ddc.

40.

Impact of HIV comprehensive care and treatment on serostatus disclosure among Cameroonian patients in rural district hospitals.

Suzan-Monti M, Kouanfack C, Boyer S, Blanche J, Bonono RC, Delaporte E, Carrieri PM, Moatti JP, Laurent C, Spire B; Stratall ANRS 12-110/ESTHER Study Group.

PLoS One. 2013;8(1):e55225. doi: 10.1371/journal.pone.0055225. Epub 2013 Jan 31.

41.

Investigating Recent Testing among MSM: Results from Community-Based HIV Rapid Testing Attendees in France.

Lorente N, Champenois K, Blanche J, Préau M, Suzan-Monti M, Mora M, Fugon L, Carrieri MP, Sagaon-Teyssier L, Le Gall JM, Spire B, Yazdanpanah Y.

J Sex Transm Dis. 2013;2013:648791. doi: 10.1155/2013/648791. Epub 2013 Jul 25.

42.

Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure.

Lafeuillade A, Soriano V, Suzan-Monti M, Stevenson M, Izopet J, Stellbrink HJ.

AIDS Res Ther. 2012 Aug 1;9(1):23. doi: 10.1186/1742-6405-9-23.

43.

Empowering HIV testing as a prevention tool: targeting interventions for high-risk men who have sex with men.

Lorente N, Suzan-Monti M, Vernay-Vaisse C, Mora M, Blanche J, Fugon L, Dhotte P, Le Gall JM, Rovera P, Carrieri MP, Préau M, Spire B.

AIDS Care. 2012;24(8):1039-45. doi: 10.1080/09540121.2012.668171. Epub 2012 Apr 23.

PMID:
22519572
44.

Individual and structural factors associated with HIV status disclosure to main partner in Cameroon: ANRS 12-116 EVAL survey, 2006-2007.

Suzan-Monti M, Blanche J, Bilé P, Koulla-Shiro S, Abu-Zaineh M, Marcellin F, Boyer S, Carrieri MP, Spire B.

J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S22-6. doi: 10.1097/QAI.0b013e31821fcfa8.

PMID:
21857281
45.

Reduced delays in time to first HIV consultation after diagnosis in France in the antiretroviral therapy era: the possible role of a free care system.

Suzan-Monti M, Fugon L, Marcellin F, Carrieri MP, Lert F, Obadia Y, Spire B; VESPA study group.

HIV Med. 2011 Jul;12(6):383-4. doi: 10.1111/j.1468-1293.2010.00893.x. No abstract available.

46.

The burden of HIV experience and care among MSM having an HIV-positive seroconcordant steady partner: a possible research hypothesis. Results from the French VESPA ANRS EN-12 study.

Suzan-Monti M, Préau M, Blanche J, Cabut S, Carrieri PM, Lert F, Obadia Y, Spire B; VESPA ANRS EN-12 Study Group.

Sex Transm Infect. 2011 Aug;87(5):396-8. doi: 10.1136/sti.2010.048660. Epub 2011 May 14.

PMID:
21572112
47.

Classification and determination of possible origins of ORFans through analysis of nucleocytoplasmic large DNA viruses.

Boyer M, Gimenez G, Suzan-Monti M, Raoult D.

Intervirology. 2010;53(5):310-20. doi: 10.1159/000312916. Epub 2010 Jun 15.

48.

Development and comparison of strain specific gag and pol real-time PCR assays for the detection of Visna/maedi virus.

Carrozza ML, Mazzei M, Bandecchi P, Fraisier C, Pérez M, Suzan-Monti M, de Andrés D, Amorena B, Rosati S, Andrésdottir V, Lujan L, Pepin M, Blacklaws B, Tolari F, Harkiss GD.

J Virol Methods. 2010 May;165(2):161-7. doi: 10.1016/j.jviromet.2010.01.013. Epub 2010 Jan 29.

PMID:
20116400
49.

Giant Marseillevirus highlights the role of amoebae as a melting pot in emergence of chimeric microorganisms.

Boyer M, Yutin N, Pagnier I, Barrassi L, Fournous G, Espinosa L, Robert C, Azza S, Sun S, Rossmann MG, Suzan-Monti M, La Scola B, Koonin EV, Raoult D.

Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21848-53. doi: 10.1073/pnas.0911354106. Epub 2009 Dec 9.

50.

Use of B7 costimulatory molecules as adjuvants in a prime-boost vaccination against Visna/Maedi ovine lentivirus.

de Andrés X, Reina R, Ciriza J, Crespo H, Glaria I, Ramírez H, Grilló MJ, Pérez MM, Andrésdóttir V, Rosati S, Suzan-Monti M, Luján L, Blacklaws BA, Harkiss GD, de Andrés D, Amorena B.

Vaccine. 2009 Jul 23;27(34):4591-600. doi: 10.1016/j.vaccine.2009.05.080. Epub 2009 Jun 16.

PMID:
19538997

Supplemental Content

Loading ...
Support Center